"In no moment in history have these issue been more apparent than during this pandemic," said Linda Wellbrock, the founder of Leading Women Entrepreneurs and the moderator for the discussion. "It's even been referred to now as the 'she-cession." The panelists were Gillian Bleimann, executive vice president at Berje Inc.; Jennifer Garrard, vice president for human resources at Brother International Inc.; Lisa Osofsky, senior partner at Mazars; and Julie Tattoni, a partner at Windels Marx.

Companies competed according to size -- 1 to 50 employees; 51 - 100 employees; and 101+ employees -- along with a category for emerging companies and for corporate citizen of the year.

The OceanFirst Financial CEO discusses the bank's recent performance, its acquisition of Partners Bancorp and the supply chain and hiring challenges facing New Jersey and the nation over the next year.

The list that unfolds over the following pages is the last such feature we’ll publish this year. Like the others – and like most of business and life in New Jersey – the Manufacturing Power 50 is shaped by the COVID-19 pandemic. The top ten individuals are drawn mostly from the pharmaceutical industry, which will provide the treatments and tools that will eventually end the outbreak. No surprise there.

The target's lead product, Tissuepatch, bonds with tissue to help control internal bleeding or prevent leaks from surgical incisions.

Facilities were evaluated based on five factors: scheduled early deliveries; C-section rates in low-risk women; newborn complications; rate of exclusive breast milk feeding; and option for vaginal births after cesarean.

The co-founder and managing principal of Onyx Equities discusses the future of office work, the firm's progress at Newark's Gateway Center and the city's revitalization. 

Nearly three years ago, Onyx Equities clinched one of the biggest real estate transactions ever in New Jersey when the firm purchased most of Newark’s Gateway Center complex. In this week's issue, co-founder Jonathan Schultz discusses his firm's work in the Brick City.

The company is focused on developing drugs to treat debilitating and sometimes deadly diseases, including infectious diseases such as COVID-19; autoimmune diseases including rheumatoid arthritis; cachexia associated with AIDS and cancer; and retinal diseases.

The developer said its choice has a proven track record in retail leasing over the past 25 years, with skills in market research, demographic analysis and identifying and securing the right tenants and creative uses for each development he oversees.

The arrangement includes a capital investment of $135 million to help strengthen the Freehold facility's integrated clinical services, physician network and infrastructure.

Lehigh Hills is located at 1400 Nursery Street and offers a collection of 273 well-appointed residences.